Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have at least CLARIFY MS Baseline data on Symbol Digit Modalities Test (SDMT)
Received at least a single dose of cladribine tablets in the CLARIFY MS study
Completed the Final Study Visit (M24) of the CLARIFY MS study
Capable of giving signed informed consent, as indicated in protocol, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol
You may not be if
Participant is considered by the Investigator and Sponsor, for any reason, to be an unsuitable candidate for the study
Participation in other studies.
Clareo Health | Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)
